Last reviewed · How we verify
Fluticasone Propionate_6
Fluticasone propionate is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors in target tissues.
Fluticasone propionate is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors in target tissues. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD), Allergic rhinitis.
At a glance
| Generic name | Fluticasone Propionate_6 |
|---|---|
| Sponsor | Imperial College London |
| Drug class | Inhaled corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Fluticasone propionate is a potent inhaled corticosteroid that reduces inflammation in the airways by activating glucocorticoid receptors, leading to decreased production of inflammatory mediators and recruitment of immune cells. It is commonly used in respiratory conditions where local anti-inflammatory action is desired with minimal systemic absorption.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD)
- Allergic rhinitis
Common side effects
- Oropharyngeal candidiasis
- Dysphonia/hoarseness
- Tremor
- Headache
- Nervousness/anxiety
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluticasone Propionate_6 CI brief — competitive landscape report
- Fluticasone Propionate_6 updates RSS · CI watch RSS
- Imperial College London portfolio CI